Posted on Leave a comment

Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis

Arthritis Research & Therapy logo
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

French court overturns ruling saying sale of cannabidiol is illegal

Flag of France

« Without considering whether the substances seized had not been legally produced in another member state of the European Union, the court failed to provide a basis for its decision. »

France’s highest appeals court

France’s highest appeals court on Wednesday overturned a ruling that stores in the country can’t legally sell cannabidiol (CBD), a non-psychotic compound related to cannabis that is being researched for a variety of medical applications, report Reuters.*

Based on the free trade of goods within the European Union, the Cour de cassation ruled that judges could not find the sale of CBD in France illegal if it had been legally produced in a member state of the bloc.*

The Court of Justice of the EU ruled last year that no national law can prohibit the sale of CBD legally produced in a member state, the French court also said.*

“Without considering whether the substances seized had not been legally produced in another member state of the European Union, the court failed to provide a basis for its decision,” it said, referring to a ruling of a lower appeals court.*

The Cour de cassation did not rule whether selling CBD in France was legal or not, and ordered a lower court to rule again on a case involving the owner of a shop selling CBD.*

“We are happy”, CBD shop owner Mathieu Bensa, who was not involved in the case, told Reuters after the ruling.*

“We did not understand why France was the last country in the European Union that had not given access to the sale of hemp plants”, he said.*

Derived mainly from the hemp plant, CBD is increasingly used as a relaxant.*

Cannabis stocks have attracted growing interest on world stock markets, particularly on the Toronto stock exchange after Canada became one of the first major economies to legalise the recreational use of marijuana.*

Cannabis use is outlawed in France but the country has one of Europe’s highest consumption rates.*

* article original

** image

*** ndlr. : –.

Posted on Leave a comment

Connecticut becomes 18th U.S. state to legalize recreational marijuana

Flag of the United States 800px

« For decades, the war on cannabis caused injustices and created disparities while doing little to protect public health and safety. »

Governor Ned Lamont

Connecticut on Tuesday joined 17 other U.S. states in legalizing adult recreational use of marijuana as Governor Ned Lamont signed a bill that he said would also help heal economic scars left by the war on drugs, report Reuters.*

The marijuana measure, which takes effect on July 1, would automatically erase many criminal convictions and would set up a regulatory structure that would direct opportunities and revenue toward communities hard-hit by its prohibition.*

“For decades, the war on cannabis caused injustices and created disparities while doing little to protect public health and safety,” Lamont said in a statement.*

Parts of the measure largely mirror a legalization bill signed by New York Governor Andrew Cuomo in March, which required that largely non-white communities that bore the brunt of drug enforcement efforts get a share of marijuana sales licenses and a share of the tax money it generates.*

Noting that some surrounding states had already legalized recreational use of the drug, Lamont said, “we’re not only effectively modernizing our laws and addressing inequities, we’re keeping Connecticut economically competitive.”*

Marijuana has been legally available for sale in neighboring Massachusetts for more than two years.*

“Regulating cannabis, rather than criminalizing it, has proven to be a superior public policy – which is why more and more states are rapidly moving in this direction,” Paul Armentano, deputy director of NORMAL, which advocates for abolition of marijuana laws, said in a statement.*

The legalization movement has gained momentum this year as five state legislatures, including Connecticut’s, have approved the drug’s recreational use, most recently in Virginia, where the law also takes effect on July 1.*

Connecticut, whose law allows for personal cultivation of marijuana plants in 2023, becomes the 18th state to approve legalization. Voters in a 19th state, South Dakota, approved legalization last year, but a legal challenge to the measure is now pending before the state Supreme Court.*

Marijuana, which remains prohibited by federal law, has been approved for medical use in 36 states, including Connecticut.*

* original article

** image

*** ndlr. : –.

Posted on Leave a comment

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis

Rheumatology logo
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

Cannabis website Leafly to raise $30 million in fresh funding

Flag of the United States 800px

« …more than 120 million people use its website annually… »

Leafly

Cannabis marketplace Leafly is raising $30 million in a fresh funding round, it said in a filing on Wednesday, as the world’s biggest pot-related website taps strong investor appetite for companies in the burgeoning U.S. marijuana industry, report Reuters.*

Seattle, Washington-based Leafly has said more than 120 million people use its website annually, with an exponential rise in popularity over the last year as several more U.S. states legalized medical or recreational use of marijuana.

Investor appetite for U.S. cannabis companies has also been supported by prospects of federal reforms, including full legalization of marijuana, after last year’s coronavirus lockdowns led a record number of people to take up cannabis use for medical or entertainment purposes.

Privately owned Leafly has raised almost $23 million of the total $30 million offering of convertible debt and equity in the latest fundraising, the company said in a filing here. It raised around $17 million in a fundraise in October 2020.

The company runs a pickup and delivery service, helps consumers find the right cannabis strain for different medical application, runs a dispensary locator and posts reviews on different cannabis products. Industry news forms a small part of its business.

Founded in 2010, Leafly was owned between 2012 and 2019 by Privateer Holdings, a cannabis-focused private equity group, and now operates as an independent business.

* original article

** image

*** ndlr. : –.

Posted on Leave a comment

Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts

Cell Death and Disease logo
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

Spasticity & Cannabis

Logo 86Avenue Sàrl
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

Amazon backs marijuana legalization, drops weed testing for some jobs

Flag of the United States 800px

« In the past, like many employers, we’ve disqualified people from working at Amazon if they tested positive for marijuana use. »

consumer boss Dave Clark

Amazon.com Inc said on Tuesday it supports a proposed U.S. legislation to legalize cannabis at the federal level, and would drop weed-testing requirements for some recruitments, report Reuters.*

The e-commerce company’s public policy team will be actively supporting The Marijuana Opportunity Reinvestment and Expungement Act of 2021 (MORE Act), which seeks to legalize marijuana at the federal level, its consumer boss Dave Clark said in a blog post.*

Amazon will also no longer screen its job applicants for marijuana use for any positions not regulated by the Department of Transportation, Clark added.*

While many U.S. states have legalized marijuana use, employers have so far largely refused to work with the industry as cannabis is still a classified substance at the federal level.*

“In the past, like many employers, we’ve disqualified people from working at Amazon if they tested positive for marijuana use,” Clark said. “However, given where state laws are moving across the U.S., we’ve changed course.”*

Amazon was hit with a proposed class action suit, which claimed that the company was violating a New York City law by testing applicants for jobs at local facilities for marijuana, according to a Westlaw report.*

The company does not allow marijuana sales on its platform.*

Amazon also said it is tweaking its worker productivity tracking tool, “Time off Task.”*

“Starting today, we’re now averaging Time off Task over a longer period to ensure that there’s more signal and less noise—reinforcing the original intent of the program,” Clark said.*

* article original

** image

*** ndlr. : –.

Posted on Leave a comment

The pharmacokinetics and the pharmacodynamics of cannabinoids

British Journal of Clinical Pharmacology
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

Endocannabinoid Signaling Pathways: Beyond CB1R and CB2R

Journal of Cell Communication and Signaling logo
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.